Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
boston blog main
boulder/denver blog main
boulder/denver top stories
cancer immunotherapy
6
×
detroit blog main
detroit top stories
indiana blog main
indiana top stories
life sciences
national
national blog main
national top stories
new york blog main
new york top stories
novartis
6
×
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
startups
6
×
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boston top stories
deals
biogen
cancer
abbvie
alzheimer's disease
clinical trials
crispr
drug prices
eli lilly
fda
What
roundup
bio
drug
acquisitions
ceo
companies
nash
new
news
pharmaceutical
price
typically
according
akcea
albert
alzheimer’s
announced
approval
bails
biggest
biogen’s
biopharmaceutical
biotech
bourla
brand
bridgebio
capital
car
cases
centers
cigarettes
collabs
company
control
convo
covid
crispr
daniel
deal
deaths
Language
unset
unknown
Current search:
novartis
×
startups
×
" cancer immunotherapy "
×
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More